Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Johnson Investment Counsel Inc.

Johnson Investment Counsel Inc. raised its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report) by 12.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,439 shares of the pharmaceutical company’s stock after purchasing an additional 1,051 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in Vertex Pharmaceuticals were worth $3,841,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Dana Investment Advisors Inc. acquired a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at $897,000. Edgemoor Investment Advisors Inc. lifted its holdings in shares of Vertex Pharmaceuticals by 1.0% during the 4th quarter. Edgemoor Investment Advisors Inc. now owns 56,382 shares of the pharmaceutical company’s stock valued at $22,942,000 after acquiring an additional 544 shares in the last quarter. Cary Street Partners Investment Advisory LLC lifted its holdings in shares of Vertex Pharmaceuticals by 2.3% during the 4th quarter. Cary Street Partners Investment Advisory LLC now owns 23,262 shares of the pharmaceutical company’s stock valued at $9,465,000 after acquiring an additional 518 shares in the last quarter. Reynders McVeigh Capital Management LLC lifted its holdings in shares of Vertex Pharmaceuticals by 14.7% during the 4th quarter. Reynders McVeigh Capital Management LLC now owns 16,141 shares of the pharmaceutical company’s stock valued at $6,568,000 after acquiring an additional 2,070 shares in the last quarter. Finally, Principal Securities Inc. acquired a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at $962,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Transactions at Vertex Pharmaceuticals

In other news, EVP Amit Sachdev sold 3,222 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,354,013.28. Following the completion of the sale, the executive vice president now directly owns 74,364 shares of the company’s stock, valued at approximately $31,250,727.36. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, COO Stuart A. Arbuckle sold 4,295 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $1,804,930.80. Following the completion of the sale, the chief operating officer now directly owns 75,718 shares of the company’s stock, valued at $31,819,732.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Amit Sachdev sold 3,222 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the sale, the executive vice president now directly owns 74,364 shares of the company’s stock, valued at $31,250,727.36. The disclosure for this sale can be found here. In the last three months, insiders sold 12,381 shares of company stock valued at $5,203,249. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

NASDAQ VRTX traded up $3.79 on Friday, hitting $422.78. The stock had a trading volume of 1,064,604 shares, compared to its average volume of 1,114,629. Vertex Pharmaceuticals Incorporated has a one year low of $320.01 and a one year high of $448.40. The company has a quick ratio of 3.78, a current ratio of 3.50 and a debt-to-equity ratio of 0.02. The stock has a market cap of $109.10 billion, a price-to-earnings ratio of 27.44, a P/E/G ratio of 2.07 and a beta of 0.39. The company’s 50-day moving average is $407.62 and its two-hundred day moving average is $401.39.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Free Report) last posted its earnings results on Monday, May 6th. The pharmaceutical company reported $4.76 EPS for the quarter, topping the consensus estimate of $3.66 by $1.10. The firm had revenue of $2.69 billion during the quarter, compared to analysts’ expectations of $2.58 billion. Vertex Pharmaceuticals had a net margin of 39.46% and a return on equity of 23.08%. Vertex Pharmaceuticals’s quarterly revenue was up 13.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.67 EPS. On average, analysts expect that Vertex Pharmaceuticals Incorporated will post 14.98 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on VRTX shares. Maxim Group lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Evercore ISI upgraded shares of Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 price objective on the stock in a report on Thursday, April 11th. StockNews.com lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday. Canaccord Genuity Group reiterated a “sell” rating and issued a $371.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday, April 12th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $440.00 price objective on shares of Vertex Pharmaceuticals in a report on Tuesday, February 20th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $432.18.

Get Our Latest Report on Vertex Pharmaceuticals

About Vertex Pharmaceuticals

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Further Reading

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.